MLYS - NASDAQ

Mineralys Therapeutics, Inc.

MLYS·NASDAQ

$25.51

+1.8%

HealthcareBiotechnology

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.69B

EPS-2.2900

P/E Ratio-11.14

Earnings Date08/11/2026

No Revenue Data

MLYS has not reported any revenue values in the available annual periods.

-154.65M

Net Income

-13%

3Y+419.0%

5Y+4414.0%

10Y+4414.0%

-142.42M

Operating Cash Flow

-14%

3Y+387.0%

5Y+5682.0%

10Y+5682.0%

Mineralys Therapeutics, Inc. Profit Bridge

MLYS · NASDAQ

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (59.00K)

Gross Profit-59.00K

Operating Expenses

Operating Expenses (170.60M)

Operating Income-170.60M

Other Income & Taxes

Interest Expense (0.00)

Other Income/Expense15.95M

Pretax Income-154.65M

Income Tax (0.00)

Net Income-154.65M

Net Income

-154.65M

Profitability Analysis

Mineralys Therapeutics, Inc. Income Statement

MLYS • NASDAQ

Mineralys Therapeutics, Inc. Income Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
REVENUE
GROSS PROFIT
Cost of Revenue	(59K)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Gross Profit	-59K	0.0	0.0	0.0	0.0	0.0
OPERATING INCOME
Operating Expenses	(170.6M)	(192.4M)	(84.7M)	(31.5M)	(18.7M)	(2.9M)
Selling, General & Administrative	(38.6M)	(23.8M)	(14.3M)	(5.2M)	(2.4M)	(532K)
Research & Development	(132M)	(168.6M)	(70.4M)	(26.3M)	(16.3M)	(2.4M)
Operating Income	-170.6M	-192.4M	-84.7M	-31.5M	-18.7M	-2.9M
PRE-TAX INCOME
Interest Expense	(0.0)	(0.0)	(0.0)	(1.7M)	(27K)	(115K)
Net Interest Income	16M	14.6M	12.8M	0.0	-27K	-115K
Total Other Income Expenses Net	16M	14.6M	12.8M	1.7M	-683K	-483K
Income Before Tax	-154.7M	-177.8M	-71.9M	-29.8M	-19.4M	-3.4M
NET INCOME
Net Income	-154.7M	-177.8M	-71.9M	-29.8M	-19.4M	-3.4M

SEC Filings

MLYS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 03, 2026	June 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	June 03, 2026	June 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 22, 2026	May 21, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 08, 2026	May 21, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 12, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 12, 2026	March 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 09, 2026	March 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 06, 2026	January 06, 2026	2026	View Filing

Showing 1 to 10 of 66 filings

Related Guides

Blog Categories

Continue your MLYS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.